Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Reports Third Quarter 2017 Financial Results
Cash Expected to Fund Operations into Q2 2018 Prescription Drug User Fee Act (PDUFA) Goal Date for Twirla® is December 26, 2017 PRINCETON, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three and...
Toggle Summary Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017
Data Suggests Twirla May Decrease Mean Length of Bleeding and Spotting Episodes...
Toggle Summary Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017
Detailed Bleeding Profile Data Provide Helpful Information for Patient Counseling PRINCETON, N.J., Oct. 16, 2017 – Agile Therapeutics, Inc., (NASDAQ: AGRX), a women’s healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational...
Toggle Summary Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy
Company Also Announces Four New Patents Granted for its Novel Transdermal Contraceptive Dosing Regimens...
Toggle Summary Agile Therapeutics to Host First Analyst Day on October 10, 2017
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City. Members of Agile's executive team will review clinical data and...
Toggle Summary Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting
PRINCETON, N.J., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract based on the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch (AG200-15) has been selected for a...
Toggle Summary Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
Presentation Scheduled on Tuesday, September 26th, 2017 at 11:30 AM ET...
Toggle Summary Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE study of its investigational low-dose combined hormonal contraceptive patch (AG200-15) has been...
Toggle Summary Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Presentation Scheduled on Tuesday, September 12th, 2017 at 9:10 AM ET...
Toggle Summary Agile Therapeutics to Present at Liolios 6th Annual Gateway Conference
Presentation Scheduled on Thursday, September 7th, 2017 at 8:00 AM PT...
Shadow